Pagoclone Indevus

Current Opinion in Investigational Drugs

Volumn 4, Issue 1, 2003, Pages 91-95

  Bateson, Alan N ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR MODULATOR; ANTIPANIC AGENT; BENZODIAZEPINE; BENZODIAZEPINE DERIVATIVE; BENZODIAZEPINE RECEPTOR AFFECTING AGENT; CYCLOPYRROLONE DERIVATIVE; DIAZEPAM; FLUMAZENIL; FLUNITRAZEPAM; LORAZEPAM; PAGOCLONE; PENTETRAZOLE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ANXIETY DISORDER; CLINICAL TRIAL; CONVULSION; DROWSINESS; DRUG APPROVAL; DRUG BINDING; DRUG BINDING SITE; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG TOXICITY; EXPERIMENTAL TEST; GENERALIZED ANXIETY DISORDER; HEADACHE; HUMAN; HYPOTHERMIA; LETHARGY; MEDICAL LITERATURE; MULTIPLE DRUG DOSE; NONHUMAN; PANIC; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; STRUCTURE ACTIVITY RELATION; TRANQUILIZING ACTIVITY; VERTIGO; WITHDRAWAL SYNDROME;

ANIMALS; ANTI-ANXIETY AGENTS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; HUMANS; NAPHTHYRIDINES; PANIC DISORDER; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037287286     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. 170327 Product profile: Anti-anxiety compound (IP-456). Interneuron Pharmaceuticals Inc Company Communication 1994
2. 186824 Effect of the cyclopyrrolones suriclone and RP-59037 on body temperature in mice. Jackson HC, Ramsay E, Nutt DJ Eur J Pharmacol 1992 216 1 23-27
3. 212798 RP 59037 and RP 60503: Anxiolytic cyclopyrrolone derivatives with low sedative potential. Interaction with the γ-aminobutyric acid A/benzodiazepine receptor complex and behavioral effects in the rodent. Doble A, Canton T, Dreisler S, Piot O, Boireau A, Stutzmann JM, Bardone MC, Rataud J, Roux M, Roussel G et al J Pharmacol Exp Ther 1993 266 3 1213-1226 This paper is a good source of references documenting partial agonists that separate anxiolytic from sedative properties.
4. 225900 Interneuron begins first pivotal trial with pagoclone for panic disorder. Interneuron Pharmaceuticals Inc Press Release 1996 November 18
5. 270040 Interneuron announces positive phase II data on pagoclone in panic disorders. Interneuron Pharmaceuticals Inc Press Release 1997 November 20
6. 283223 Pagoclone non-confidential summary - September 1997. Interneuron Pharmaceuticals Inc Company Brochure 1997 September 01
7. 294941 Interneuron's pagoclone significantly reduces panic attacks in phase 2/3 clinical trial. Drug achieves primary endpoint, advances in clinical development. Interneuron Pharmaceuticals Inc Press Release 1998 August 17
8. 351570 Interneuron licenses worldwide rights for pagoclone to Warner-Lambert for panic and generalized anxiety disorders. Interneuron Pharmaceuticals Inc Press Release 1999 December 27
9. 375962 US major pharmaceutical model and pipeline book: 1st quarter 2000 issue. Merrill Lynch Capital Markets 2000 May
10. 382124 Interneuron announces initiation of clinical testing of pagoclone by Pfizer. Interneuron Pharmaceuticals Inc Press Release 2000 September 12
11. 393715 Interneuron pharmaceuticals announces fiscal 2000 year end results. Interneuron Pharmaceuticals Inc Press Release 2000 December 14
12. 396166 Interneuron announces initiation of phase II clinical testing of pagoclone in generalized anxiety disorder; Phase III trial in panic disorder ongoing. Interneuron Pharmaceuticals Inc Press Release 2001 January 16
13. 398857 Interneuron Pharmaceuticals announces first quarter fiscal 2001 results. Interneuron Pharmaceuticals Inc Press Release 2001 February 13
14. 420809 Pharmaceutical Desk Reference: Global equities research US - Our models of the major US pharma companies. Lehman Brothers Inc 2001 August
15. 424570 Anxiolytic-like effects of pagaclone. Kinsora JJ, Fillhard JA, Serpa KA, Snyder BJ, Meltzer LT Abstr Soc Neurosci 2000 26 1-2 Abs 866.19
16. 434117 Interneuron provides pagoclone update following Pfizer report of positive results in generalized anxiety disorder. Interneuron Pharmaceuticals Inc Press Release 2001 December 18
17. 447816 Crossover trial of pagoclone and placebo in patients with DSM-IV panic disorder. Sandford JJ, Forshall S, Bell C, Argyropoulos S, Rich A, D'Orlando KJ, Gammans RE, Nutt DJ J Psychopharmacol 2001 15 3 205-208
18. A receptor α1 subtype. McKernan RM, Rosahl TW, Reynolds DS, Sur C, Wafford KA, Atack JR, Farrar S, Myers J, Cook G, Ferris P, Garrett L et al Nat Neurosci 2000 3 6 587-592
19. 453955 Pfizer returns pagoclone to indevus. Indevus Pharmaceuticals Inc Press Release 2002 June 07
20. A receptor subtypes. Rudolph U, Crestani F, Benke D, Brunig I, Benson JA, Fritschy JM, Martin JR, Bluethmann H, Mohler H Nature 1999 401 6755 796-800
21. 459351 Panic disorder: Long-term pharmacotherapy and discontinuation. Rickels K, Schweizer E J Clin Psychopharmacol 1998 18 6 (Suppl 2) 12S-18S
22. A/Benzodiazepine Receptor as a Target for Psychoactive Drugs Eds: Doble A, Martin IL Oxford University Press UK 1996
23. 459369 Comparative pharmacology of benzodiazepine receptor ligands with differing intrinsic efficacy. Haefley W In: Transmitter Amino Acid Receptors: Structures, Transduction and Models for Drug Development Eds: Barnard EA, Costa E Raven Press New York NY USA 1991 91-111
24. 462772 Indevus announces conclusion of discussions with Aventis on pagoclone. Indevus Pharmaceuticals Inc Press Release August 29 2002